RxCelerate, an out-sourced drug discovery and development company in the United Kingdom, has expanded to the United States, opening an office in Cambridge, MA. They have also appointed Laura Hamilton as executive vice president for U.S. Operations.

The company, founded in 2012 in Cambridge, England, offers a fully integrated discovery and development service to the pharma and biotech industry, ranging from medicinal chemistry, antibody discovery, preclinical safety, and efficacy through to clinical proof of concept. 

With Department for International Trade (DIT) support over the last two years, RxCelerate began to develop their international trade strategy and looked to expand their business abroad. DIT Advisers provided the company with local market insights, advice on export strategy, and connected them to key target companies in the U.S., leading to a significant increase in export business in 2017. That then led to the opening of their new Massachusetts office.

“We are deeply integrated into the life sciences ecosystem. With our new U.S. base, that ecosystem just got a whole lot bigger,” said David Grainger, executive chairman at RxCelerate.